Table 1.
Main characteristics of the included publications.
| Publication | Year | Country | Patient number | Gender | Antibody | Cutoff (low/high level) | Method | Outcome | TNM stage | Mean age (years) | Median follow-up (months) | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adams et al. | 2009 | Switzerland | 938 | 422/510 | NR | High (>5%) | IHC | OS | I–IV | 70.5 | 128 | 7 |
| Betge et al. | 2016 | Germany | 381 | 215/166 | Ccp-58 | High (>0%) | IHC | OS/DFS | I–IV | 68.5 | NR | 8 |
| Elzagheid et al. | 2013 | Libya | 141 | 55/86 | MRQ-18 | High (>0%) | IHC | OS/DFS | I–IV | NR | 77 | 8 |
| Imai et al. | 2013 | Japan | 250 | 136/114 | Ccp-58 | High (≥25%) | IHC | OS/RFS | I–IV | NR | NR | 8 |
| Kang et al. | 2011 | Korea | 229 | NR | NR | High (staining score ≥ 6) | IHC | OS | II-III | NR | 108 | 7 |
| Khanh et al. | 2013 | Japan | 206 | 114/92 | Ccp-58 | High (≥5%) | IHC | OS/RFS | I–IV | NR | NR | 8 |
| Lu et al. | 2014 | China | 60 | 33/27 | Ccp-58 | High (>5%) | IHC | OS | I–IV | 52.9 | NR | 8 |
| Perez et al. | 2008 | Brazil | 35 | 20/15 | Ccp-58 | High (>10%) | IHC | OS/DFS | I–IV | 62.2 | NR | 7 |
| Wang et al. | 2017 | China | 139 | 76/63 | NCL-MUC2 | High (>20%) | IHC | OS | II–IV | NR | NR | 8 |
| Yu et al. | 2007 | China | 150 | 95/55 | Ccp-58 | High (staining score ≥ 2) | IHC | OS | I–IV | 57.5 | NR | 8 |
| Zwenger et al. | 2014 | Argentina | 90 | 52/38 | H300 | High (staining score > 0) | IHC | OS | I–IV | NR | NR | 8 |
IHC: immunohistochemistry; OS: overall survival; DFS: disease-free survival; RFS: recurrence-free survival; NR: not reported; NOS score: Newcastle-Ottawa Scale score.